Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol
Primary Purpose
Delirium
Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Melatonin
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Delirium focused on measuring Delirium
Eligibility Criteria
Inclusion Criteria:
- Patients 65 years of age and older undergoing Low Energy Lower Extremity Fractures (LELEF) surgery
- Presence of an LELEF fracture
- Low Energy (e.g., falls from standing height, falls from sitting, etc.).
Operative Fractures:
- Pathologic femur and tibia fractures
- Femoral neck fractures
- Pertroch: including intertroch, subtroch fractures
- Femoral shaft
- Supracondylar femur fractures
- Periprosthetic fractures around total hip and total knee arthroplasties
- Tibial plateau fractures
- Proximal Tibia Fractures
- Tibial Shaft Fractures
- Distal 1/3 tibia fractures
- Ankle Fractures that are admitted
Exclusion Criteria:
- Patients with previous adverse reaction or side-effects to melatonin
- Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
- Inability to communicate in English
- Patients with a Montreal Cognitive Assessment (MoCA) score of below 7 will not be included in the study because of their inability to give informed consent at that stage. This score is approximately 2 standard deviation below average score for Alzheimer's Dementia.
- Participants who are unable to give consent or communicate well in English will not be enrolled
Sites / Locations
- Loyola University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
Melatonin
Arm Description
Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
Outcomes
Primary Outcome Measures
Delirium assessment
The Delirium Rating Scale Revised (DRS-R98) will be given to all patients every day for seven days. Investigators will compare the scores recorded on day 7 between those receiving melatonin versus those receiving placebo controlling for their baseline performance.
Secondary Outcome Measures
Hospital stay
Length of hospital stay will be recorded for all patients and compared between the two treatment groups (i.e., those receiving melatonin and those receiving placebo).
Full Information
NCT ID
NCT02903901
First Posted
September 13, 2016
Last Updated
September 15, 2016
Sponsor
Loyola University
1. Study Identification
Unique Protocol Identification Number
NCT02903901
Brief Title
Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol
Official Title
Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Withdrawn
Why Stopped
Investigator found that a new study drug that is FDA approved would be superior to melatonin
Study Start Date
June 2015 (undefined)
Primary Completion Date
June 2018 (Anticipated)
Study Completion Date
June 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Loyola University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To test the efficacy of melatonin compared to placebo in preventing post-operative delirium and reduction in intensity or duration of delirium in individuals 65 years of age and older who undergo orthopedic surgery after low energy lower extremity fractures (LELEF).
Biomarkers may play important roles in the detection, prediction and management of delirium especially in frail elderly individuals. Predictive biomarkers may help characterize an individual's susceptibility to delirium and thereby help specialized treatment, care and management of such individuals during their hospitalization. They may also help predict treatment response to a specific modality and help in selection of such modality. Recent studies performed in the UK and published in 2011 have measured plasma cholinesterase activity and determined that these levels were lower in patients who developed delirium compared with remaining subjects. Other studies have indicated that CRP may also have a role in delirium prediction as they have found that CRP measured on admission to an ICU had predictable changes that occurred within 24 hours that in turn were predictors of delirium. One the aims of the study is to compare the predictive and treatment response values of groups of biomarkers that have been hypothesized to be of predictive value.
Detailed Description
Surgery causes oxidative stress on the brain9 leading to inflammation. Post-operative delirium has been linked with inflammation in the brain. Delirium has been hypothesized to be a central nervous system response to systemic inflammation during a state of blood-brain barrier (BBB) compromise.
Studies have shown a rise of inflammatory cytokines and fall of anti-inflammatory cytokines. Vice-versa, external cytokine administration has been shown to lead to delirium. Melatonin is known for its strong anti-oxidant and anti-inflammatory properties, this should account for its preventive properties in post-operative delirium. It has also been hypothesized that post-operative delirium in elderly is caused by circadian rhythm disturbances secondary to a relative lack of melatonin.
Keeping in mind the above two possible pathophysiology for delirium, investigators are expecting melatonin supplementation should be able to reduce the incidence of post-operative delirium particularly in elderly population.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium
Keywords
Delirium
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
Arm Title
Melatonin
Arm Type
Active Comparator
Arm Description
Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
Intervention Type
Drug
Intervention Name(s)
Melatonin
Intervention Description
10 mg liquid Melatonin IR-SL at 7 pm for 1 week
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
10 mg liquid placebo at 7 pm for 1 week
Primary Outcome Measure Information:
Title
Delirium assessment
Description
The Delirium Rating Scale Revised (DRS-R98) will be given to all patients every day for seven days. Investigators will compare the scores recorded on day 7 between those receiving melatonin versus those receiving placebo controlling for their baseline performance.
Time Frame
1 Week
Secondary Outcome Measure Information:
Title
Hospital stay
Description
Length of hospital stay will be recorded for all patients and compared between the two treatment groups (i.e., those receiving melatonin and those receiving placebo).
Time Frame
1 Week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients 65 years of age and older undergoing Low Energy Lower Extremity Fractures (LELEF) surgery
Presence of an LELEF fracture
Low Energy (e.g., falls from standing height, falls from sitting, etc.).
Operative Fractures:
Pathologic femur and tibia fractures
Femoral neck fractures
Pertroch: including intertroch, subtroch fractures
Femoral shaft
Supracondylar femur fractures
Periprosthetic fractures around total hip and total knee arthroplasties
Tibial plateau fractures
Proximal Tibia Fractures
Tibial Shaft Fractures
Distal 1/3 tibia fractures
Ankle Fractures that are admitted
Exclusion Criteria:
Patients with previous adverse reaction or side-effects to melatonin
Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
Inability to communicate in English
Patients with a Montreal Cognitive Assessment (MoCA) score of below 7 will not be included in the study because of their inability to give informed consent at that stage. This score is approximately 2 standard deviation below average score for Alzheimer's Dementia.
Participants who are unable to give consent or communicate well in English will not be enrolled
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muralidhara S Rao, MD
Organizational Affiliation
Loyola University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Loyola University Medical Center
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
20007989
Citation
Deiner S, Silverstein JH. Postoperative delirium and cognitive dysfunction. Br J Anaesth. 2009 Dec;103 Suppl 1(Suppl 1):i41-46. doi: 10.1093/bja/aep291.
Results Reference
background
PubMed Identifier
12817919
Citation
Bekker AY, Weeks EJ. Cognitive function after anaesthesia in the elderly. Best Pract Res Clin Anaesthesiol. 2003 Jun;17(2):259-72. doi: 10.1016/s1521-6896(03)00005-3.
Results Reference
background
Learn more about this trial
Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol
We'll reach out to this number within 24 hrs